ERBB2 and neoplasm: These genes were selected among those expressed more by the tumor-initiating cells than by the non-tumor-initiating ones, thus obtaining a prognostic tool that was able to predict metastasis-free survival (MFS) and OS in HER2+/ERα− cancer patients.